摘要
目的探讨环磷酰胺联合泼尼松在系统性红斑狼疮治疗中的疗效及安全性。方法采用随机数字表法将2014年1月~2017年12月本院接收的系统性红斑狼疮患者58例分为对照组和观察组,对照组29例实施泼尼松单一治疗,观察组29例实施泼尼松联合环磷酰胺治疗。将两组系统性红斑狼疮患者的临床效果、免疫球蛋白水平、补体水平、血清炎症因子指标、不良反应发生情况进行比较。结果观察组系统性红斑狼疮患者的临床总有效率(93.10%)高于对照组,差异有统计学意义(P <0.05);观察组治疗后的免疫球蛋白水平、补体水平、血清炎症因子指标均显著低于对照组,差异有统计学意义(P <0.05);两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论环磷酰胺联合泼尼松应用于系统性红斑狼疮患者的治疗中安全有效。
Objective To explore curative effects and safety of cyclophosphamide combined with prednisone in treatment of systemic lupus erythematosus. Methods 58 patients with systemic lupus erythematosus who were admitted to our hospital from January 2014 to December 2017 were divided into the control group and the observation group according to the random number table method.29 patients in the control group were treated with prednisonealone while 29 patients in the observation group were treated with prednisone combined with cyclophosphamide.Clinical curative effects,immunoglobulin levels,complement levels,serum inflammatory factor indexes and adverse reactions of patients with systemic lupus erythematosus in two groups were compared. Results The total clinical effective rate(93.10%)of the patients with systemic lupus erythematosus in the observation group was higher than that in the control group,and the difference was statistically significant(P < 0.05).After treatment,immunoglobulin levels,complement levels,serum inflammatory factor indexes in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P < 0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion Cyclophosphamide combined with prednisone in treatment of patients with systemic lupus erythematosusis safe and effective.
作者
陈波
梁洁
CHEN Bo;LIANG Jie(Department of Intrarenal Rheumatology,Heyuan People’s Hospital,Guangdong,Heyuan 517000,China)
出处
《中国医药科学》
2019年第16期72-74,233,共4页
China Medicine And Pharmacy
关键词
系统性红斑狼疮
泼尼松
环磷酰胺
安全性
Systemic lupus erythematosus
Prednisone
Cyclophosphamide
Safety
